People in this study will be placed into one of two groups by chance, like flipping a coin. One group will get two medicines called DSP107 and Atezolizumab together. The other group will get a medicine called Fruquintinib by itself. Each treatment cycle lasts 4 weeks and can continue for up to 2 years. Doctors will check health and safety during the study. After the last dose, there will be a follow-up period of up to 90 days.

Advanced Microsatellite Stable Colorectal Cancer

People can join this study if they are 18 years or older and are expected to live for more than 3 months. They must have a type of colon cancer called microsatellite stable (MSS) or proficient mismatch repair (pMMR) colorectal cancer.

The goal of this study is to learn if people with a type of colon cancer called microsatellite stable colorectal cancer do better when treated with two medicines, DSP107 and Atezolizumab, compared to those who get Fruquintinib.